PureTech Health plc

LSE:PRTC Stock Report

Market Cap: UK£409.9m

PureTech Health Valuation

Is PRTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRTC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRTC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRTC?

Key metric: As PRTC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PRTC. This is calculated by dividing PRTC's market cap by their current book value.
What is PRTC's PB Ratio?
PB Ratio1.6x
BookUS$315.87m
Market CapUS$513.61m

Price to Book Ratio vs Peers

How does PRTC's PB Ratio compare to its peers?

The above table shows the PB ratio for PRTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average38.8x
OXB Oxford Biomedica
6.7x93.2%UK£442.5m
BVXP Bioventix
16.3xn/aUK£195.7m
FARN Faron Pharmaceuticals Oy
130.1x17.3%UK£149.1m
GNS Genus
2.1x37.7%UK£1.1b
PRTC PureTech Health
1.6x-13.0%UK£409.9m

Price-To-Book vs Peers: PRTC is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (38.8x).

Price to Book Ratio vs Industry

How does PRTC's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
PRTC 1.6xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PRTC is good value based on its Price-To-Book Ratio (1.6x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is PRTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRTC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PRTC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRTC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.71
UK£5.59
+226.7%
18.6%UK£6.64UK£4.55n/a2
Nov ’25UK£1.55
UK£5.59
+260.0%
18.6%UK£6.64UK£4.55n/a2
Oct ’25UK£1.41
UK£5.48
+287.4%
17.6%UK£6.44UK£4.51n/a2
Sep ’25UK£1.63
UK£5.40
+231.4%
15.7%UK£6.25UK£4.56n/a2
Aug ’25UK£1.70
UK£5.42
+219.8%
16.2%UK£6.30UK£4.55n/a2
Jul ’25UK£1.83
UK£5.42
+197.1%
16.2%UK£6.30UK£4.55n/a2
May ’25UK£2.14
UK£4.93
+130.1%
26.6%UK£6.24UK£3.61n/a2
Apr ’25UK£2.23
UK£4.67
+109.7%
23.8%UK£6.20UK£3.60n/a3
Mar ’25UK£2.02
UK£4.68
+131.7%
23.9%UK£6.23UK£3.62n/a3
Feb ’25UK£1.94
UK£5.70
+194.2%
45.0%UK£9.30UK£3.60n/a3
Jan ’25UK£1.94
UK£5.71
+193.9%
44.9%UK£9.31UK£3.61n/a3
Dec ’24UK£1.52
UK£5.69
+274.3%
45.0%UK£9.30UK£3.63n/a3
Nov ’24UK£1.49
UK£5.90
+294.7%
40.6%UK£9.28UK£4.04UK£1.553
Oct ’24UK£1.81
UK£5.78
+219.5%
42.6%UK£9.26UK£3.88UK£1.413
Sep ’24UK£2.00
UK£5.78
+189.1%
42.6%UK£9.26UK£3.88UK£1.633
Aug ’24UK£2.21
UK£5.87
+165.6%
41.3%UK£9.30UK£4.09UK£1.703
Jul ’24UK£2.18
UK£5.87
+169.9%
41.3%UK£9.30UK£4.09UK£1.833
Jun ’24UK£2.17
UK£5.96
+174.8%
40.3%UK£9.36UK£4.20UK£2.343
May ’24UK£2.10
UK£5.96
+184.6%
40.3%UK£9.36UK£4.20UK£2.143
Apr ’24UK£2.22
UK£6.35
+186.8%
33.2%UK£9.33UK£4.71UK£2.233
Mar ’24UK£2.20
UK£5.98
+171.7%
39.4%UK£9.30UK£4.12UK£2.023
Feb ’24UK£2.47
UK£5.98
+142.5%
39.4%UK£9.30UK£4.12UK£1.943
Jan ’24UK£2.67
UK£6.03
+126.2%
38.3%UK£9.28UK£4.20UK£1.943
Dec ’23UK£2.87
UK£6.54
+128.4%
31.1%UK£9.36UK£4.64UK£1.523
Nov ’23UK£2.43
UK£6.78
+179.2%
26.9%UK£9.29UK£4.99UK£1.493

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%